SHEZF.US Shenzhen Hepalink Pharmaceutical Group Co. Ltd

Healthcare Pharmaceuticals USA Stocks
3.13 USD
Close of Nov 18, 2026
0.4484 0.4696
Market cap
USD 689M
P/E
-
P/B
0.40x
ROE
4.4%
Dividend yield
7.43%
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is SHEZF.US undervalued?

Graham number

The Graham number of Shenzhen Hepalink Pharmaceutical Group Co. Ltd cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Shenzhen Hepalink Pharmaceutical Group Co. Ltd fundamental analysis

No fundamental analysis for Shenzhen Hepalink Pharmaceutical Group Co. Ltd yet.

Shenzhen Hepalink Pharmaceutical Group Co. Ltd stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Shenzhen Hepalink Pharmaceutical Group Co. Ltd

Shenzhen Hepalink Pharmaceutical Group Co., Ltd. provides pharmaceutical products in Hong Kong, the United States, Europe, Mainland China, and internationally. It operates in four segments: Pharmaceutical preparations, Active Pharmaceutical Ingredients (API), Contract Development and Manufacturing Organization (CDMO), and Others. The company offers pharmaceutical preparations products, such as enoxaparin sodium injection; API products, including heparin and enoxaparin sodium…

Full company profile